Literature DB >> 18093685

Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.

Diana Orejuela1, Rossana Jorquera, Anne Bergeron, Milton J Finegold, Robert M Tanguay.   

Abstract

BACKGROUND/AIMS: The AKT survival pathway is involved in a wide variety of human cancers. We investigated the implication of this pathway in hereditary tyrosinemia type 1 (HT1), a metabolic disease exhibiting hepatocellular carcinoma (HCC), despite treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexadione (NTBC) which prevents liver damage. HT1 is an autosomal recessive disorder caused by accumulation of toxic metabolites due to a deficiency in fumarylacetoacetate hydrolase (FAH), the last enzyme in the catabolism of tyrosine.
METHODS: NTBC withdrawal in the murine fah(-/-) knockout model was used to analyze in vivo the correlation between pathophysiological, biochemical and histological features consistent with hepatocarcinogenesis and activation of the AKT survival pathway.
RESULTS: The HT1 stress initiated by NTBC discontinuation causes a progressive increase of liver and kidney pathophysiology. A stable activation of the AKT survival pathway is observed in the liver but not in kidneys of fah(-/-) mice. Hepatic survival is reinforced by inhibition of mitochondrial-mediated apoptosis through inactivation of Bad and induction of BCl-X(L) and BCl-2.
CONCLUSIONS: The chronic stress induced by liver disease in HT1 activates the AKT survival signal and inhibits intrinsic apoptosis to confer cell death resistance in vivo and favor hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18093685     DOI: 10.1016/j.jhep.2007.09.014

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  12 in total

1.  Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Authors:  Etresia van Dyk; Pieter J Pretorius
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

2.  Proteomic profiling of differentially expressed proteins from Bax inhibitor-1 knockout and wild type mice.

Authors:  Bo Li; John C Reed; Hyung-Ryong Kim; Han-Jung Chae
Journal:  Mol Cells       Date:  2012-06-25       Impact factor: 5.034

3.  Modeling hepatitis B virus X-induced hepatocellular carcinoma in mice with the Sleeping Beauty transposon system.

Authors:  Vincent W Keng; Barbara R Tschida; Jason B Bell; David A Largaespada
Journal:  Hepatology       Date:  2011-01-03       Impact factor: 17.425

4.  Kidney ECM Pregel Nanoarchitectonics for Microarrays to Accelerate Harvesting Gene-Edited Porcine Primary Monoclonal Spheres.

Authors:  Mengyu Gao; Xinglong Zhu; Wanliu Peng; Yuting He; Yi Li; Qiong Wu; Yanyan Zhou; Guangneng Liao; Guang Yang; Ji Bao; Hong Bu
Journal:  ACS Omega       Date:  2022-06-29

Review 5.  Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects.

Authors:  Kara R Vogel; Andrew A Kennedy; Luke A Whitehouse; K Michael Gibson
Journal:  J Inherit Metab Dis       Date:  2013-10-02       Impact factor: 4.982

Review 6.  Liver tumors in children with metabolic disorders.

Authors:  Deborah A Schady; Angshumoy Roy; Milton J Finegold
Journal:  Transl Pediatr       Date:  2015-10

7.  Heat shock response associated with hepatocarcinogenesis in a murine model of hereditary tyrosinemia type I.

Authors:  Francesca Angileri; Geneviève Morrow; Vincent Roy; Diana Orejuela; Robert M Tanguay
Journal:  Cancers (Basel)       Date:  2014-04-23       Impact factor: 6.639

Review 8.  Senescence and cell death in chronic liver injury: roles and mechanisms underlying hepatocarcinogenesis.

Authors:  Mengchao Xiao; Wenjian Chen; Chao Wang; Yingfu Wu; Shiwei Zhu; Chuyang Zeng; Yongchao Cai; Changcheng Liu; Zhiying He
Journal:  Oncotarget       Date:  2017-12-22

9.  Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice.

Authors:  Sebene Mayorandan; Uta Meyer; Gülden Gokcay; Nuria Garcia Segarra; Hélène Ogier de Baulny; Francjan van Spronsen; Jiri Zeman; Corinne de Laet; Ute Spiekerkoetter; Eva Thimm; Arianna Maiorana; Carlo Dionisi-Vici; Dorothea Moeslinger; Michaela Brunner-Krainz; Amelie Sophia Lotz-Havla; José Angel Cocho de Juan; Maria Luz Couce Pico; René Santer; Sabine Scholl-Bürgi; Hanna Mandel; Yngve Thomas Bliksrud; Peter Freisinger; Luis Jose Aldamiz-Echevarria; Michel Hochuli; Matthias Gautschi; Jessica Endig; Jens Jordan; Patrick McKiernan; Stefanie Ernst; Susanne Morlot; Arndt Vogel; Johannes Sander; Anibh Martin Das
Journal:  Orphanet J Rare Dis       Date:  2014-08-01       Impact factor: 4.123

10.  Identification of circulating microRNAs during the liver neoplastic process in a murine model of hereditary tyrosinemia type 1.

Authors:  Francesca Angileri; Geneviève Morrow; Jean-Yves Scoazec; Nicolas Gadot; Vincent Roy; Suli Huang; Tangchun Wu; Robert M Tanguay
Journal:  Sci Rep       Date:  2016-06-10       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.